We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Stryker to Report Q1 Earnings: What's in Store for the Stock?
Read MoreHide Full Article
Key Takeaways
Stryker is set to report Q1 results with EPS seen up 4.9% and revenue rising 7.3% year over year.
SYK growth is driven by strong procedure demand, Mako adoption and robust capital equipment orders.
Tariffs, higher interest costs and uneven capital spending may pressure margins despite solid growth.
Stryker Corporation (SYK - Free Report) is scheduled to release first-quarter 2026 results on April 30, after market close. In the last reported quarter, the company delivered an earnings surprise of 1.59%.
Q1 Estimates
The Zacks Consensus Estimate for earnings is pegged at $2.98 per share, indicating an increase of 4.9% year over year.
The consensus mark for revenues is pinned at $6.29 billion, implying growth of 7.3% from the prior-year reported figure.
Our model estimates for total sales and adjusted earnings per share are pegged at $7.11 billion and $4.35, respectively.
Factors to Note
Stryker's first-quarter results are likely to reflect the continuation of strong momentum in 2025, with management highlighting sustained procedural demand, robust capital equipment ordering and continued innovation-led growth across its portfolio. Organic sales growth has consistently remained in the double-digit range, supported by healthy hospital capital spending and rising adoption of robotic-assisted surgery, particularly the Mako platform. However, the quarter is likely to reflect incremental cost pressures from tariffs, higher interest expenses and geographic variability in capital spending trends.
Segment-wise, MedSurg and Neurotechnology are expected to have remained key growth drivers. Demand for capital equipment such as surgical tools, endoscopy systems and medical devices like LIFEPAK 35 and ProCuity beds is likely to have supported double-digit growth, aided by an elevated order backlog. Continued product innovation, sales force specialization and tuck-in acquisitions should have further bolstered performance in this segment. However, a softer capital spending environment in parts of Europe could have acted as a modest headwind.
In Orthopedics, growth is likely to have remained solid, driven by Mako robotic system installations and rising utilization in knee and hip procedures. Continued adoption of advanced implants and strong shoulder and trauma demand should support performance, although tougher prior-year comparisons and some softness in foot and ankle may have tempered growth.
Within Vascular, performance may have been mixed, with strength in hemorrhagic products likely to have been offset by ongoing competitive pressures in ischemic offerings. The Inari (peripheral vascular) business is expected to have reflected recovery from prior destocking impacts, supporting sequential improvement.
On the margin front, pricing discipline and operational efficiencies should have aided profitability, though tariff impacts — expected to rise meaningfully — along with higher interest costs may have partially offset gains. Overall, Stryker’s diversified portfolio, innovation pipeline and strong procedural backdrop are likely to have sustained earnings growth, albeit with some near-term margin pressures.
Our proven model does not conclusively predict an earnings beat for Stryker this time around. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the chances of an earnings beat. This is not the case here, as you will see below.
Earnings ESP: Earnings ESP, which represents the difference between the Most Accurate Estimate and the Zacks Consensus Estimate, is -2.21% for SYK. You can uncover the best stocks to buy or sell before they're reported with our Earnings ESP Filter.
Zacks Rank: The company carries a Zacks Rank #3 at present.
Stocks Worth a Look
Here are some medical product stocks worth considering, as these have the right combination of elements to post an earnings beat this reporting cycle.
Microbot Medical (MBOT - Free Report) has an Earnings ESP of +8.70% and a Zacks Rank of 2 at present.
MBOT’s earnings surpassed estimates in two of the trailing four quarters and missed twice, with the average surprise being 7.53%. The Zacks Consensus Estimate for MBOT’s first-quarter loss per share implies no change from the year-ago reported figure.
Henry Schein (HSIC - Free Report) has an Earnings ESP of +0.28% and a Zacks Rank #3 at present. The company is slated to release first-quarter 2026 results on May 5.
HSIC’s earnings surpassed estimates in three of the trailing four quarters and missed once, with the average surprise being 2.14%. The Zacks Consensus Estimate for HSIC’s first-quarter EPS indicates an improvement of 4.4% from the year-ago reported figure.
IDEXX Laboratories (IDXX - Free Report) has an Earnings ESP of +0.77% and a Zacks Rank of 3 at present. The company is slated to release first-quarter 2026 results on May 5.
IDXX’s earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 6.11%. The Zacks Consensus Estimate for IDXX’s first-quarter EPS indicates a gain 15.5% from the year-ago reported figure.
Zacks' 7 Best Strong Buy Stocks (New Research Report)
Valued at $99, click below to receive our just-released report
predicting the 7 stocks that will soar highest in the coming month.
View the Zacks #1 Rank List
Image: Bigstock
Stryker to Report Q1 Earnings: What's in Store for the Stock?
Key Takeaways
Stryker Corporation (SYK - Free Report) is scheduled to release first-quarter 2026 results on April 30, after market close. In the last reported quarter, the company delivered an earnings surprise of 1.59%.
Q1 Estimates
The Zacks Consensus Estimate for earnings is pegged at $2.98 per share, indicating an increase of 4.9% year over year.
The consensus mark for revenues is pinned at $6.29 billion, implying growth of 7.3% from the prior-year reported figure.
Our model estimates for total sales and adjusted earnings per share are pegged at $7.11 billion and $4.35, respectively.
Factors to Note
Stryker's first-quarter results are likely to reflect the continuation of strong momentum in 2025, with management highlighting sustained procedural demand, robust capital equipment ordering and continued innovation-led growth across its portfolio. Organic sales growth has consistently remained in the double-digit range, supported by healthy hospital capital spending and rising adoption of robotic-assisted surgery, particularly the Mako platform. However, the quarter is likely to reflect incremental cost pressures from tariffs, higher interest expenses and geographic variability in capital spending trends.
Segment-wise, MedSurg and Neurotechnology are expected to have remained key growth drivers. Demand for capital equipment such as surgical tools, endoscopy systems and medical devices like LIFEPAK 35 and ProCuity beds is likely to have supported double-digit growth, aided by an elevated order backlog. Continued product innovation, sales force specialization and tuck-in acquisitions should have further bolstered performance in this segment. However, a softer capital spending environment in parts of Europe could have acted as a modest headwind.
In Orthopedics, growth is likely to have remained solid, driven by Mako robotic system installations and rising utilization in knee and hip procedures. Continued adoption of advanced implants and strong shoulder and trauma demand should support performance, although tougher prior-year comparisons and some softness in foot and ankle may have tempered growth.
Within Vascular, performance may have been mixed, with strength in hemorrhagic products likely to have been offset by ongoing competitive pressures in ischemic offerings. The Inari (peripheral vascular) business is expected to have reflected recovery from prior destocking impacts, supporting sequential improvement.
On the margin front, pricing discipline and operational efficiencies should have aided profitability, though tariff impacts — expected to rise meaningfully — along with higher interest costs may have partially offset gains. Overall, Stryker’s diversified portfolio, innovation pipeline and strong procedural backdrop are likely to have sustained earnings growth, albeit with some near-term margin pressures.
Stryker Corporation Price and EPS Surprise
Stryker Corporation price-eps-surprise | Stryker Corporation Quote
What the Zacks Model Unveils
Our proven model does not conclusively predict an earnings beat for Stryker this time around. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the chances of an earnings beat. This is not the case here, as you will see below.
Earnings ESP: Earnings ESP, which represents the difference between the Most Accurate Estimate and the Zacks Consensus Estimate, is -2.21% for SYK. You can uncover the best stocks to buy or sell before they're reported with our Earnings ESP Filter.
Zacks Rank: The company carries a Zacks Rank #3 at present.
Stocks Worth a Look
Here are some medical product stocks worth considering, as these have the right combination of elements to post an earnings beat this reporting cycle.
Microbot Medical (MBOT - Free Report) has an Earnings ESP of +8.70% and a Zacks Rank of 2 at present.
MBOT’s earnings surpassed estimates in two of the trailing four quarters and missed twice, with the average surprise being 7.53%. The Zacks Consensus Estimate for MBOT’s first-quarter loss per share implies no change from the year-ago reported figure.
Henry Schein (HSIC - Free Report) has an Earnings ESP of +0.28% and a Zacks Rank #3 at present. The company is slated to release first-quarter 2026 results on May 5.
HSIC’s earnings surpassed estimates in three of the trailing four quarters and missed once, with the average surprise being 2.14%. The Zacks Consensus Estimate for HSIC’s first-quarter EPS indicates an improvement of 4.4% from the year-ago reported figure.
IDEXX Laboratories (IDXX - Free Report) has an Earnings ESP of +0.77% and a Zacks Rank of 3 at present. The company is slated to release first-quarter 2026 results on May 5.
IDXX’s earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 6.11%. The Zacks Consensus Estimate for IDXX’s first-quarter EPS indicates a gain 15.5% from the year-ago reported figure.